HC Wainwright Reiterates Buy Rating on NVCR
HC Wainwright maintains its optimistic stance on NVCR, setting a $46 price target, a 212.82% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating on NVCR on June 18, 2026, with a price target of $46.
- HC Wainwright's $46 price target implies 212.82% upside from NovoCure Limited's ($NVCR) current $14.71 share price.
- NVCR shares trade around $14.71, with insider activity showing recent purchases and sales by company executives.
- Institutional investors like FMR LLC and BlackRock have adjusted their holdings in NVCR, reflecting diverse strategies.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 18, 2026, HC Wainwright reiterated its buy rating on NVCR, setting a price target of $46. This reflects continued confidence in the company's prospects despite its current trading price of approximately $14.71.
Other Institutional Activity in NVCR
Institutional investors have been actively adjusting their positions in NVCR. FMR LLC grew its holdings by 272,170 shares, ending with 17,069,149 shares valued at about $186.1 million. In contrast, BlackRock, Inc. reduced its stake by 347,683 shares, maintaining 13,193,765 shares worth approximately $143.8 million. Soleus Capital Management, L.P. significantly increased its holdings by 1,961,726 shares, bringing its total to 10,492,391 shares valued at $114.4 million. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both established new positions with 6,251,701 and 4,682,064 shares, respectively. Meanwhile, Morgan Stanley trimmed its holdings by 528,369 shares, retaining 4,541,526 shares worth about $49.5 million.
NovoCure Limited Stock Down 17.5%
NVCR shares are currently trading near $14.71. The stock has seen recent fluctuations, with institutional investors making notable adjustments to their holdings. These movements reflect varying strategies and confidence levels among major investors.
$NVCR price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at NovoCure Limited
Recent insider activity at NVCR includes several transactions. On June 4, 2026, CEO Leonard Frank sold 34,273 shares at an average price of $17.93. Meanwhile, on June 3, 2026, Martin Madden, along with Anthony Vernon, Timothy Scannell, and David Hung, each acquired shares in the company. These purchases were made at a price of $0, indicating potential stock grants or awards.
Analysts Set New Price Targets
On June 18, 2026, HC Wainwright & Co. reiterated its buy rating on NVCR, setting a price target of $46. In May, Wells Fargo maintained a hold rating with a $17 target, while Evercore ISI Group kept its buy rating and a $20 target. The analyst consensus suggests a mixed outlook, with varying levels of optimism about NVCR's future performance.
About NVCR
NVCR is a healthcare company focused on the development and commercialization of treatments for solid tumor cancers. Based in the United States, the company is known for its innovative approaches to cancer therapy. NVCR's mission is to improve the lives of cancer patients through groundbreaking research and development.
Bottom Line
Analyst activity, insider transactions, and institutional movements provide a comprehensive view of NVCR's current market dynamics. HC Wainwright's reiterated buy rating and $46 price target underscore confidence in the company's long-term potential. Investors should consider these insights with the understanding that 13F filings and analyst ratings are backward-looking and may not reflect the most current positions or sentiments.
Get NovoCure Limited alerts
New 13F filings, insider trades, and analyst moves on $NVCR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.